p2

Cambridge Healthtech Institute’s Inaugural

Vector Design and Development for Gene and Cell Therapies

Engineering Safer and More Efficacious Vectors

January 20-21, 2020

Part of the Cell & Gene Therapies pipeline

 

The recent success in gene and cell therapies has necessitated a resurgence in vector engineering. Research and development efforts focusing on vectors to combine low genotoxicity and immunogenicity with efficient delivery have shown promise. However, numerous delivery challenges must be overcome, including developing techniques to evade preexisting immunity to ensure more efficient transduction of therapeutically relevant cell types, to target delivery, and to ensure genomic maintenance. Fortunately, vector design and development efforts are overcoming these barriers and demonstrating clinical successes.

Cambridge Healthtech Institute’s Inaugural Vector Design and Development for Gene and Cell Therapies conference convenes molecular biologists, cell-line developers, process developers, vector engineers, material scientists, synthetic biologists, biochemists, geneticists, immunologists, and virologists from biotech and pharma companies along with clinicians who are driving the advancement of gene and cell therapies into the clinic.

 

Coverage will include, but is not limited to:

  • Viral Vectors
  • Synthetic Vectors
  • Plasmid Vectors
  • Exosome Vectors
  • Gene Targets
  • Delivery
  • Host Cell Lines
  • Immunogenicity
  • Genomic Stability
  • Production
  • Regulations
  • Case Studies

 

* The program is subject to change without notice, due to unforeseen reason.







2020 Conferences & Training Seminars